95 related articles for article (PubMed ID: 17201122)
21. Modulation of the activation of Stat1 by the interferon-gamma receptor complex.
Krause CD; He W; Kotenko S; Pestka S
Cell Res; 2006 Jan; 16(1):113-23. PubMed ID: 16467883
[TBL] [Abstract][Full Text] [Related]
22. IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor.
Yuan H; Liddle FJ; Mahajan S; Frank DA
Carcinogenesis; 2004 Nov; 25(11):2247-55. PubMed ID: 15284182
[TBL] [Abstract][Full Text] [Related]
23. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
Tanaka H; Ito T; Kyo T; Kimura A
Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976
[TBL] [Abstract][Full Text] [Related]
24. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Fuke H; Shiraki K; Sugimoto K; Tanaka J; Beppu T; Yoneda K; Yamamoto N; Ito K; Masuya M; Takei Y
Biochem Biophys Res Commun; 2007 Nov; 363(3):738-44. PubMed ID: 17904524
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
26. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers.
Kassouf N; Thornhill MH
Oral Oncol; 2008 Jul; 44(7):672-82. PubMed ID: 17996489
[TBL] [Abstract][Full Text] [Related]
27. Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
Uchida M; Iwase M; Takaoka S; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
Int J Oncol; 2007 May; 30(5):1163-71. PubMed ID: 17390018
[TBL] [Abstract][Full Text] [Related]
28. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
29. Amplification of the signal transducer and activator of transcription I signaling pathway and its association with apoptosis in monocytes from HIV-infected patients.
Alhetheel A; Yakubtsov Y; Abdkader K; Sant N; Diaz-Mitoma F; Kumar A; Kryworuchko M
AIDS; 2008 Jun; 22(10):1137-44. PubMed ID: 18525259
[TBL] [Abstract][Full Text] [Related]
30. Human mast cells express intracellular TRAIL.
Berent-Maoz B; Salemi S; Mankuta D; Simon HU; Levi-Schaffer F
Cell Immunol; 2010; 262(2):80-3. PubMed ID: 20189551
[TBL] [Abstract][Full Text] [Related]
31. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
David E; Sinha R; Chen J; Sun SY; Kaufman JL; Lonial S
Clin Cancer Res; 2008 Aug; 14(16):5090-8. PubMed ID: 18698026
[TBL] [Abstract][Full Text] [Related]
32. [Study of molecular mechanism of doxorubicin enhancement of TRAIL, inducing apoptosis of myeloma cell line KM3].
Wang HF; Chen ZH; Sun CY; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):30-2. PubMed ID: 17649723
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
34. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
Kusaba M; Nakao K; Goto T; Nishimura D; Kawashimo H; Shibata H; Motoyoshi Y; Taura N; Ichikawa T; Hamasaki K; Eguchi K
J Hepatol; 2007 Oct; 47(4):546-55. PubMed ID: 17602782
[TBL] [Abstract][Full Text] [Related]
35. STAT1 phosphorylation and cleavage is regulated by the histamine (H4) receptor in human atopic and non-atopic lymphocytes.
Horr B; Borck H; Thurmond R; Grösch S; Diel F
Int Immunopharmacol; 2006 Oct; 6(10):1577-85. PubMed ID: 16919830
[TBL] [Abstract][Full Text] [Related]
36. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1.
Lui VW; Boehm AL; Koppikar P; Leeman RJ; Johnson D; Ogagan M; Childs E; Freilino M; Grandis JR
Mol Pharmacol; 2007 May; 71(5):1435-43. PubMed ID: 17325127
[TBL] [Abstract][Full Text] [Related]
37. IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha.
Tsuno T; Mejido J; Zhao T; Schmeisser H; Morrow A; Zoon KC
J Immunother; 2009 Oct; 32(8):803-16. PubMed ID: 19752753
[TBL] [Abstract][Full Text] [Related]
38. Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells.
Okada T; Sawada T; Kubota K
Cancer Lett; 2007 Apr; 248(1):24-31. PubMed ID: 16837131
[TBL] [Abstract][Full Text] [Related]
39. Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells.
Lee J; Jung HH; Im YH; Kim JH; Park JO; Kim K; Kim WS; Ahn JS; Jung CW; Park YS; Kang WK; Park K
Oncol Rep; 2006 Jun; 15(6):1541-9. PubMed ID: 16685393
[TBL] [Abstract][Full Text] [Related]
40. Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient.
Otsuki T; Hata H; Harada N; Matsuzaki H; Yata K; Wada H; Yawata Y; Ueki A; Yamada O
Int J Hematol; 2000 Aug; 72(2):216-22. PubMed ID: 11039672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
